- Home
- GGAL vs KRYS Comparison
GGAL vs KRYS Comparison
Compare GGAL & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGAL
- KRYS
- Stock Information
- Founded
- GGAL 1905
- KRYS 2015
- Country
- GGAL Argentina
- KRYS United States
- Employees
- GGAL N/A
- KRYS N/A
- Industry
- GGAL Commercial Banks
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GGAL Finance
- KRYS Health Care
- Exchange
- GGAL Nasdaq
- KRYS Nasdaq
- Market Cap
- GGAL 5.2B
- KRYS 4.7B
- IPO Year
- GGAL N/A
- KRYS 2017
- Fundamental
- Price
- GGAL $46.23
- KRYS $217.14
- Analyst Decision
- GGAL Strong Buy
- KRYS Strong Buy
- Analyst Count
- GGAL 5
- KRYS 9
- Target Price
- GGAL $75.67
- KRYS $214.22
- AVG Volume (30 Days)
- GGAL 3.0M
- KRYS 333.3K
- Earning Date
- GGAL 03-07-2023
- KRYS 11-03-2025
- Dividend Yield
- GGAL 1.82%
- KRYS N/A
- EPS Growth
- GGAL N/A
- KRYS 275.72
- EPS
- GGAL 0.60
- KRYS 6.66
- Revenue
- GGAL $4,565,013,669.00
- KRYS $373,164,000.00
- Revenue This Year
- GGAL $9.54
- KRYS $34.33
- Revenue Next Year
- GGAL $12.92
- KRYS $48.04
- P/E Ratio
- GGAL $8.50
- KRYS $31.83
- Revenue Growth
- GGAL N/A
- KRYS 54.51
- 52 Week Low
- GGAL $25.89
- KRYS $122.80
- 52 Week High
- GGAL $74.00
- KRYS $214.72
- Technical
- Relative Strength Index (RSI)
- GGAL 44.74
- KRYS 74.20
- Support Level
- GGAL $53.39
- KRYS $203.17
- Resistance Level
- GGAL $57.20
- KRYS $212.97
- Average True Range (ATR)
- GGAL 2.54
- KRYS 7.18
- MACD
- GGAL -1.83
- KRYS 0.59
- Stochastic Oscillator
- GGAL 8.69
- KRYS 97.76
About GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.